Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Themes AI

The Future of Longevity: AI and Nanorobots to Radically Extend Life

by Team Lumida
June 25, 2024
in AI, Health and Longevity
Reading Time: 3 mins read
A A
0
person holding black and white microscope

Photo by Jaron Nix on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

  1. AI-driven drug discovery could drastically cut down clinical trial times.
  2. Medical nanorobots may revolutionize immune systems by the 2030s.
  3. By 2040s, mind-backup systems might allow near-immortality.

What Happened?

Futurist Ray Kurzweil claims that AI will revolutionize drug discovery and medical interventions by the end of the 2020s. He believes biological simulators will soon generate crucial safety and efficacy data in hours, not years.

This shift could lead to faster drug approvals and save countless lives. Kurzweil also predicts that medical nanorobots will emerge in the 2030s, vastly enhancing our immune systems and treating metabolic diseases. By 2040s, he envisions mind-backup systems that could essentially render death obsolete.

Why It Matters?

These advancements could disrupt traditional medical models and extend human lifespans dramatically. Faster drug approvals would mean quicker access to lifesaving treatments. Medical nanorobots could address diseases that our natural immune systems can’t, such as cancer and neurodegenerative disorders.

The potential to back up our minds might lead to radical life extension, fundamentally changing the concept of mortality. Investors should note the profound implications for the healthcare and biotech sectors, which could experience exponential growth.

What’s Next?

Expect increased investment in AI-driven pharmaceutical research and biotech firms focused on nanotechnology. Regulatory landscapes will evolve to accommodate simulated trials, despite potential bureaucratic resistance. By the mid-2040s, mind-backup technologies will likely face ethical and security challenges, but Kurzweil is optimistic about overcoming these hurdles.

As these technologies become mainstream, they will likely follow the trajectory of the cell phone—starting expensive and exclusive, but eventually becoming widely accessible.

Source: Fortune Well
Tags: AI-driven drug discoverymedical nanorobotsmind-backup systemsRay Kurzweil
Previous Post

Bitcoin Crashes to $62K: What’s Behind the $150M Liquidation?

Next Post

TikTok Ban Could Dent Oracle’s Earnings: What Investors Need to Know

Recommended For You

EU to Designate ChatGPT and Roblox as ‘Very Large Online Platforms’ — Triggering DSA’s Strictest Compliance Rules

by Team Lumida
8 hours ago
OpenAI Hack: Why AI Companies Are Prime Targets for Cyberattacks

The European Commission will designate OpenAI's ChatGPT and Roblox as 'very large online platforms' under the Digital Services Act as soon as August, after both surpassed 45 million...

Read more

Zuckerberg to Congress: Optimism About AI Should Be the Default — America Must Accelerate, Not Restrict

by Team Lumida
1 day ago
a white square with a blue logo on it

Meta CEO Mark Zuckerberg testified before Congress that the U.S. should accelerate AI development rather than restrict it, arguing that optimism about AI's benefits should be the empirical...

Read more

Trump Administration to End $3.6 Billion Medicare Drug Premium Subsidy — Seniors Face Higher Part D Costs in 2027

by Team Lumida
1 day ago
Supreme Court Signals It Will Strike Down Trump’s Birthright Citizenship Order

The Trump administration will not renew the Part D Low Income Premium Subsidy program after 2026, eliminating $3.6 billion in annual payments to insurers that have been holding...

Read more

AI Boom Mints a Selling Wave: Nvidia, CoreWeave, Broadcom Insiders Pocket $4+ Billion in Q2

by Team Lumida
1 day ago
Nvidia’s Stock: Is It Too Good to Be True Now?

Eight of the top 10 insider sellers in Q2 2026 were tied to the AI supply chain, cashing out a combined $4+ billion as the Philadelphia Semiconductor Index...

Read more

Anthropic’s Amodei Rejects Open-Model Ban but Calls for Mandatory Safety Testing — Drawing a Clear Line From Nvidia and OpenAI’s Pro-Open-Source Coalition

by Team Lumida
2 days ago
Pentagon–Anthropic Feud Escalates as AI Policy Clash Threatens Defense Contracts

Anthropic CEO Dario Amodei denied the company supports a ban on open-weight AI models while simultaneously refusing to sign the Nvidia-Microsoft-OpenAI letter opposing restrictions — calling instead for...

Read more

80% of People Are Deficient in Essential Vitamins — Here Are the 10 You Actually Need and Where to Get Them

by Team Lumida
3 days ago
oranges, peas, and limes on a wooden table

Most people are not getting enough of the 13 essential vitamins their bodies require — here is a practical guide to the most critical nutrients, what they do,...

Read more

Nvidia to Backstop $250 Billion for OpenAI’s Ohio Data Center — the Largest AI Infrastructure Deal Ever Attempted

by Team Lumida
3 days ago
Nvidia’s Stock: Is It Too Good to Be True Now?

Nvidia is in talks to provide a $250 billion financial guarantee for OpenAI's lease of a 10-gigawatt data-center complex in southern Ohio being developed by SoftBank's energy subsidiary,...

Read more

Moonshot AI Releases Kimi K3 Weights — World’s Largest Open-Weight Model at 2.8 Trillion Parameters Enters the Global AI Race

by Team Lumida
3 days ago
Moonshot AI Releases Kimi K3 Weights — World’s Largest Open-Weight Model at 2.8 Trillion Parameters Enters the Global AI Race

China's Moonshot AI is releasing the weights of its Kimi K3 model for free public download, making the world's largest open-weight AI model at 2.8 trillion parameters freely...

Read more

SoftBank’s $40 Billion OpenAI Bridge Loan Draws 21 New Lenders — Abu Dhabi, Singapore’s GIC, and Standard Chartered Each Take ~$1 Billion

by Team Lumida
3 days ago
SoftBank’s Narrow Gain: How AI Investments Shape the Future

SoftBank's $40 billion bridge loan backing its OpenAI investment has entered broader syndication, attracting 21 new lenders including First Abu Dhabi Bank, Singapore's GIC, and Standard Chartered —...

Read more

How OpenAI’s Rogue AI Models Hacked Hugging Face — And Why Congress Just Introduced a Bipartisan AI ‘Kill Switch’ Bill

by Team Lumida
6 days ago
OpenAI Hack: Why AI Companies Are Prime Targets for Cyberattacks

New WSJ reporting details how OpenAI's AI models — described as 'like high school students hacking the textbook company to cheat on their final exam' — autonomously escaped...

Read more
Next Post
a red cube with white text

TikTok Ban Could Dent Oracle's Earnings: What Investors Need to Know

a person holding a phone

AI and Crypto Shakeup: Nvidia and Bitcoin's Massive Drops Explained

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Japan’s Exports to U.S. Decline as Tariffs Take a Toll on Trade

Japan’s Exports to U.S. Decline as Tariffs Take a Toll on Trade

May 21, 2025
Nvidia CEO Reveals Secrets Behind AI Domination Amidst Fierce Competition

Nvidia Stock Nears Full Recovery from DeepSeek-Induced Rout, Boosted by New Demand

February 18, 2025
Goldman Predicts US Job Market Shift: Stands by Two Rate Cut Forecast

Goldman Sachs: Trump’s Tariffs to Lift Baseline Rate to 15%, Fueling Inflation and Slowing Growth

July 23, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018